Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1824-1832

  Nouhi, Zaynab ^a   Chughtai, Naila ^a   Hartley, Strachan ^a   Cocolakis, Eftihia ^a   Lebrun, Jean Jacques ^a   Ali, Suhad ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROLACTIN; RECOMBINANT PROTEIN; SMAD PROTEIN; STAT5A PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INVASION; CELL DIFFERENTIATION; CELL GROWTH; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CHO CELLS; CRICETINAE; ENZYME ACTIVATION; EPITHELIAL CELLS; HUMANS; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; MESODERM; NEOPLASM INVASIVENESS; PROLACTIN; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; SMAD PROTEINS;

EID: 32944469616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2292     Document Type: Article

References (62)

1. Nicoll CS. Ontogeny and evolution of prolactin's functions. Fed Proc 1980;39:2563-6.
2. Ormandy CJ, Naylor M, Harris J, et al. Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. Recent Prog Horm Res 2003;58:297-323.
3. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-68.
4. Horseman ND, Zhao W, Montecino-Rodriguez E, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997;16:6926-35.
5. Ormandy CJ, Camus A, Barra J, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-78.
6. Wagner KU, Krempler A, Triplett AA, et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004;24:5510-20.
7. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997;11:179-86.
8. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
9. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002;13:245-50.
10. Vonderhaar BK. Prolactin: the forgotten hormone of human breast cancer. Pharmacol Ther 1998;79:169-78.
11. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-5.
12. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 1995;146:695-705.
13. Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667-74.
14. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis [In Process Citation]. Clin Cancer Res 1999;5:3583-93.
15. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R Int J Oncol 2002;20:813-8.
16. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003;144:5300-7.
17. Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 1995;270:13133-7.
18. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003;22:4664-74.
19. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000;19:1077-84.
20. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003;83:337-76.
21. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003;4:657-65.
22. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
23. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
24. Tang B, Vu M, Booker T, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;112:1116-24.
25. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
26. Muraoka RS, Koh Y, Roebuck LR, et al. Increased malignancy of Neu-induced mammary tumors over-expressing active transforming growth factor beta1. Mol Cell Biol 2003;23:8691-703.
27. Ali S, Ali S. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways. J Biol Chem 1998;273:7709-16.
28. Ali S, Chen Z, Lebrun JJ, et al. PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation. EMBO J 1996;15:135-42.
29. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990;1:99-106.
30. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89.
31. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-45.
32. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
33. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004;49:179-86.
34. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38 Suppl 5:811-8.
35. Zhuang H, Patel SV, He TC, Sonsteby SK, Niu Z, Wojchowski DM. Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J Biol Chem 1994;269:21411-4.
36. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
37. Santen RJ, Song RX McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002;80:239-56.
38. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395-403.
39. Acosta JJ, Munoz RM, Gonzalez L, et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 2003;17:2268-82.
40. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol Endocrinol 2004;18:3064-75.
41. Lehmann K, Janda E, Pierreux CE, et al. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000;14:2610-22.
42. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
43. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 2004;23:1668-80.
44. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005;24:746-60.
45. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63.
46. Shevde LA, Welch DR. Metastasis suppressor pathways: an evolving paradigm. Cancer Lett 2003;198:1-20.
47. Hartsough MT, Morrison DK, Salerno M, et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway. J Biol Chem 2002;277:32389-99.
48. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000;10:1009-12.
49. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003;19:91-118.
50. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
51. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 2004;16:769-79.
52. Wang Y, Waldron RT, Dhaka A, et al. The RAS effector RTN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 2002;22:916-26.
53. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999;401:173-7.
54. Matheny SA, Chen C, Kortum RL, Razidlo GL, Lewis RE, White MA. Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 2004;427:256-60.
55. Hanafusa H, Torii S, Yasunaga T, Nishida E. Sproutyl and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 2002;4:850-8.
56. Wakioka T, Sasaki A, Kato R, et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001;412:647-51.
57. Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997;88:197-204.
58. Yamanashi Y, Baltimore D. Identification of the Abl-and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997;88:205-11.
59. Sandberg EM, Ma X VonDerLinden D, Godeny MD, Sayeski PP. Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1. J Biol Chem 2004;279:1956-67.
60. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005;7:291-3.
61. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases In cancer. Cancer Metastasis Rev 2003;22:423-34.
62. Luo C, Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 2004;9:268-75.